Gyre Therapeutics, INC Form 4 insider transactions

Claire Weston, a Director of Gyre Therapeutics, Inc., received 40,000 shares of common stock on August 3, 2026.

Maxwell Kirkby, a Director of Gyre Therapeutics, Inc., received 40,000 shares of common stock on August 3, 2026.

Gordon Carmichael, a Director at Gyre Therapeutics, Inc., has acquired stock options for 40,000 shares.

David M. Epstein, a Director at Gyre Therapeutics, Inc., has acquired 40,000 stock options with an exercise price of $5.95.

Gyre Therapeutics Director Dan Weng acquired 40,000 stock options with an exercise price of $5.95, vesting over 12 months.

Renate Parry, a Director at Gyre Therapeutics, Inc., has acquired 40,000 stock options with an exercise price of $5.95, vesting over 12 months.

Ping Zhang, a Director at Gyre Therapeutics, Inc., has acquired stock options for 40,000 shares, with vesting scheduled over 12 months.

Rodney L. Nussbaum, a Director at Gyre Therapeutics, Inc., was granted 40,000 stock options with an exercise price of $5.95.

Gyre Therapeutics Chief Operating Officer, Ye Weiguo, reported transactions involving the sale of common stock and the exercise of stock options.

Gyre Therapeutics Chief Operating Officer, Ye Weiguo, reported transactions involving the acquisition and disposition of company stock, including the exercise of stock options.

Joshua Bergmann, General Counsel and Corporate Secretary of Gyre Therapeutics, was granted 50,000 stock options.

Gyre Therapeutics CEO Ying Luo was granted 120,000 stock options with an exercise price of $6.05.

Gyre Therapeutics Chief Operating Officer, Ye Weiguo, reported transactions involving the purchase and sale of company common stock.

Gyre Therapeutics Chief Operating Officer Ye Weiguo reported transactions involving the acquisition and sale of company common stock and stock options.

Gyre Therapeutics Chief Operating Officer Weiguo Ye exercised options and sold 22,220 shares of common stock.

Director Ping Zhang has canceled 250,000 stock options in Gyre Therapeutics, Inc. by mutual agreement with the issuer.

Gyre Therapeutics Chief Operating Officer Ye Weiguo reported transactions involving the acquisition and disposition of company stock.

Gyre Therapeutics Chief Operating Officer, Ye Weiguo, reported transactions involving the sale of company stock.

Gyre Therapeutics CEO Ying Luo disposed of 10,315 shares of common stock through a pre-arranged Rule 10b5-1 trading plan.

GNI Group Ltd. and GNI USA, Inc. reported the acquisition of Series B Preferred Stock in Gyre Therapeutics, Inc. following the merger with Cullgen Inc.

Gyre Therapeutics CFO Thomas Eastling reported the acquisition of multiple stock option tranches in a Form 4 filing.

GYRE Therapeutics Director Ping Zhang was granted 100,000 stock options with an exercise price of $7.31, vesting over four years.

GYRE Therapeutics' Chief Financial Officer, Ruoyu Chen, was granted 50,000 stock options with an exercise price of $7.31, vesting over four years.

GYRE Therapeutics Director Dan Weng received a grant of 52,000 stock options with an exercise price of $7.85, vesting over three years.

GYRE Therapeutics Director Ping Zhang was granted options to purchase 250,000 shares of common stock with a $6.92 exercise price.

GYRE Therapeutics, Inc. Director Thomas Wilson Eastling was granted 26,000 stock options with an exercise price of $8.58, vesting over 12 months.

GYRE Therapeutics, Inc. Director David M. Epstein has been granted stock options to acquire 26,000 shares of common stock at an exercise price of $8.58, with vesting occurring in monthly installments over the next year.

GYRE Therapeutics Director Rodney L. Nussbaum has acquired 26,000 stock options with an exercise price of $8.58, vesting monthly over one year.

Renate Parry, a Director at GYRE Therapeutics, Inc., was granted 26,000 stock options with an exercise price of $8.58, vesting monthly over one year.

A recent SEC Form 4 filing reveals that Gordon Carmichael, a Director at GYRE Therapeutics, Inc., was granted 26,000 stock options with an exercise price of $8.58, vesting over 12 months.